Amneal Biosciences, a wholly-owned subsidiary of Amneal Pharmaceuticals LLC, has launched its first commercial product.
Fosphenytoin sodium injection, USP, is available in 100 mg PE* / 2 mL (50 mg PE / mL) strength in a 25-count pack of single-dose vials and 500 mg PE / 10 mL (50 mg PE / mL) strength in a 10-pack of single-dose vials. The product began shipping in August.
“We at Amneal Biosciences are very excited about the launch of our first product and its ability to address industry shortages in hospitals, clinics, and acute care facilities. Fosphenytoin, along with our other upcoming launches, is fully aligned with the strategic direction of the company,” said Amneal Biosciences president Charles Lucarelli.
According to July 2016 IMS market data, annual (MAT) U.S. sales of the brand Cerebyx® and its generic equivalents totaled $38 million.